{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:10:54Z","timestamp":1790125854252,"version":"4.0.1"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472167, 82273691"],"award-info":[{"award-number":["82472167, 82273691"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20241982"],"award-info":[{"award-number":["BK20241982"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005273","name":"Natural Science Foundation of Yunnan Province","doi-asserted-by":"publisher","award":["2019FA005"],"award-info":[{"award-number":["2019FA005"]}],"id":[{"id":"10.13039\/501100005273","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013072","name":"Major Science and Technology Project of Hainan Province","doi-asserted-by":"publisher","award":["LCYX202204, LCYX202306"],"award-info":[{"award-number":["LCYX202204, LCYX202306"]}],"id":[{"id":"10.13039\/501100013072","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>Low-level viremia (LLV) in chronic hepatitis B (CHB) represents a significant challenge and area of interest in current clinical management. While nucleos (t)ide analogs (NAs) have demonstrated substantial efficacy in suppressing hepatitis B virus (HBV) replication, the application of highly sensitive detection methods has revealed that some treated patients continue to exhibit persistent or intermittent low-level viremia (HBV DNA: 12\u20132000 IU\/mL). The mechanisms underlying LLV involve a synergistic interplay between host immune response deficiencies and HBV covalently closed circular DNA (cccDNA) persistence. Furthermore, the complex regulation of LLV is influenced by metabolic-associated steatotic liver disease (MASLD). Limitations in the clearance of cccDNA by current antiviral regimens also contribute to this phenomenon. LLV may elevate the risk of liver fibrosis progression, hepatocellular carcinoma (HCC), and end-stage liver disease. Current management strategies emphasize optimizing antiviral regimens, such as switching to tenofovir alafenamide (TAF) or combining therapies with pegylated interferon-alpha (Peg-IFN-\u03b1). Enhanced dynamic monitoring, including high-sensitivity HBV DNA assays and quantitative hepatitis B surface antigen (HBsAg) measurements, is also crucial. Moreover, exploring combination therapies involving immunomodulation and hepatocyte regeneration is warranted. Further research should integrate multi-omics technologies with prospective cohort studies to elucidate the host-virus interaction network in LLV. This will allow for the validation of synergistic effects between metabolic interventionsand immunotherapy, thereby advancing personalized precision medicine. This review systematically synthesizes the epidemiological characteristics, pathogenesis, influencing factors, prognosis, and clinical management advancements of LLV, aiming to provide novel perspectives for optimizing therapeutic strategies and translational research.<\/jats:p>","DOI":"10.3389\/fcimb.2025.1663858","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:38:09Z","timestamp":1763534289000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Unveiling low level viremia in chronic hepatitis B: challenges and new horizons"],"prefix":"10.3389","volume":"15","author":[{"given":"Bingqing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengrui","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqin","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanlong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1136\/gutjnl-2016-312162","article-title":"Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo","volume":"67","author":"Allweiss","year":"2018","journal-title":"Gut"},{"key":"B2","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1046\/j.1365-2567.2003.01699.x","article-title":"Hepatitis B virus-induced defect of monocyte-derived dendritic cells leads to impaired T helper type 1 response in vitro: mechanisms for viral immune escape","volume":"109","author":"Beckebaum","year":"2003","journal-title":"Immunology."},{"key":"B3","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.jhep.2016.01.026","article-title":"Adaptive immunity in HBV infection","volume":"64","author":"Bertoletti","year":"2016","journal-title":"J. Hepatol."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.imj.2024.100087","article-title":"HBsAg kinetics after 7 years of therapy with tenofovir disoproxil fumarate in a cohort of na\u00efve patients affected by chronic hepatitis B with different genotypes","volume":"3","author":"Boglione","year":"2024","journal-title":"Infect. Med. (Beijing)."},{"key":"B5","doi-asserted-by":"publisher","first-page":"G211","DOI":"10.1152\/ajpgi.00040.2019","article-title":"CD8+ T cells regulate liver injury in obesity-related nonalcoholic fatty liver disease","volume":"318","author":"Breuer","year":"2020","journal-title":"Am. J. Physiol. Gastrointest Liver Physiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"4588","DOI":"10.1172\/JCI121960","article-title":"Circulating and intrahepatic antiviral B cells are defective in hepatitis B","volume":"128","author":"Burton","year":"2018","journal-title":"J. Clin. Invest."},{"key":"B7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/liv.13641","article-title":"Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B","author":"Buti","year":"2018","journal-title":"Liver Int."},{"key":"B8","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/jgh.16357","article-title":"Risk factors of low-level viremia in chronic hepatitis B patients receiving Entecavir monotherapy: a retrospective cohort study","volume":"39","author":"Chen","year":"2024","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.7150\/ijms.95861","article-title":"Risk factors and nomogram model for hepatocellular carcinoma development in chronic hepatitis B patients with low-level viremia","volume":"21","author":"Chen","year":"2024","journal-title":"Int. J. Med. Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"6634","DOI":"10.4049\/jimmunol.178.10.6634","article-title":"B7-H1 up-regulation on myeloid dendritic cells significantly suppresses T cell immune function in patients with chronic hepatitis B","volume":"178","author":"Chen","year":"2007","journal-title":"J. Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.3760\/cma.j.cn311365-20230220-00050","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)","volume":"30","year":"2022","journal-title":"J. Pract. Hepatalogy"},{"key":"B12","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/sj.ijo.0803479","article-title":"Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection","volume":"31","author":"Chu","year":"2007","journal-title":"Int. J. Obes. (Lond)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"83","year":"2025","journal-title":"J. Hepatol."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00849","article-title":"Pathogenetic mechanisms of T cell dysfunction in chronic HBV infection and related therapeutic approaches","volume":"11","author":"Fisicaro","year":"2020","journal-title":"Front. Immunol."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20210600","article-title":"Serum HBV pregenomic RNA exhibited opposite associations with NKdim and NKbright cell immunity in treatment-na\u00efve chronic hepatitis B patients","volume":"41","author":"Gu","year":"2021","journal-title":"Biosci. Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1007\/s12250-020-00337-9","article-title":"Cell cycle arrest protein CDKN2C is not an HBV host factor","volume":"36","author":"Guan","year":"2021","journal-title":"Virol. Sin."},{"key":"B17","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/j.1872-034X.2007.00279.x","article-title":"Human plasmacytoid dendritic cells from patients with chronic hepatitis B virus infection induce the generation of a higher proportion of CD4(+) and CD25(+) regulatory T cells compared with healthy patients","volume":"38","author":"Hong","year":"2008","journal-title":"Hepatol. Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.cgh.2023.09.040","article-title":"Metabolic dysfunction-associated steatotic liver disease facilitates hepatitis B surface antigen seroclearance and seroconversion","volume":"22","author":"Huang","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/jvh.12766","article-title":"Inverse relationship between hepatic steatosis and hepatitis B viremia: Results of a large case-control study","volume":"25","author":"Hui","year":"2018","journal-title":"J. Viral Hepat."},{"key":"B20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41577-021-00549-4","article-title":"Immunobiology and pathogenesis of hepatitis B virus infection","volume":"22","author":"Iannacone","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1111\/liv.12768","article-title":"An intrahepatic transcriptional signature of enhanced immune activity predicts response to peginterferon in chronic hepatitis B","volume":"35","author":"Jansen","year":"2015","journal-title":"Liver Int."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.21037\/atm-21-3052","article-title":"Concurrence and impact of hepatic steatosis on chronic hepatitis B patients: a systematic review and meta-analysis","volume":"9","author":"Jiang","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1084109","article-title":"Prospects for NK-based immunotherapy of chronic HBV infection","volume":"13","author":"Jin","year":"2022","journal-title":"Front. Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e34198","DOI":"10.1371\/journal.pone.0034198","article-title":"Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B","volume":"7","author":"Jin","year":"2012","journal-title":"PloS One"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.759292","article-title":"Peripheral immune cells exhaustion and functional impairment in patients with chronic hepatitis B","volume":"8","author":"Jin","year":"2021","journal-title":"Front. Med. (Lausanne)."},{"key":"B26","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/hep.24121","article-title":"Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan)","volume":"53","author":"Jung","year":"2011","journal-title":"Hepatology."},{"key":"B27","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2217\/fvl.14.36","article-title":"Strategies to eliminate HBV infection","volume":"9","author":"Kapoor","year":"2014","journal-title":"Future Virol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/hep.28916","article-title":"Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment","volume":"66","author":"Kim","year":"2017","journal-title":"Hepatology."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1111\/jgh.14750","article-title":"Hepatitis B virus DNA levels and overall survival in hepatitis B-related hepatocellular carcinoma patients with low-level viremia","volume":"34","author":"Kim","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jhep.2019.04.010","article-title":"Efficient long-term amplification of hepatitis B virus isolates after infection of slow proliferating HepG2-NTCP cells","volume":"71","author":"K\u00f6nig","year":"2019","journal-title":"J. Hepatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.4254\/wjh.v7.i8.1030","article-title":"Current and future antiviral drug therapies of hepatitis B chronic infection","volume":"7","author":"Koumbi","year":"2015","journal-title":"World J. Hepatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1053\/j.gastro.2020.04.019","article-title":"Effects of hepatitis B surface antigen on virus-specific and global T cells in patients with chronic hepatitis B virus infection","volume":"159","author":"Le Bert","year":"2020","journal-title":"Gastroenterology."},{"key":"B33","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.jhep.2016.12.024","article-title":"Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B","volume":"66","author":"Leboss\u00e9","year":"2017","journal-title":"J. Hepatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/s0168-8278(98)80314-0","article-title":"Reduction in hepatic cytochrome P-450 is correlated to the degree of liver fat content in animal models of steatosis in the absence of inflammation","volume":"28","author":"Leclercq","year":"1998","journal-title":"J. Hepatol."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1413589","article-title":"Risk factors related to low-level viraemia in chronic hepatitis B patients receiving entecavir treatment","volume":"14","author":"Li","year":"2024","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1111\/liv.14415","article-title":"Fatty liver is not independently associated with the rates of complete response to oral antiviral therapy in chronic hepatitis B patients","volume":"40","author":"Li","year":"2020","journal-title":"Liver Int."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/liv.14786","article-title":"Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia","volume":"41","author":"Li","year":"2021","journal-title":"Liver Int."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.4254\/wjh.v16.i12.1395","article-title":"Influence of nonalcoholic fatty liver disease on the therapeutic effect of nucleoside (acid) analogs for hepatitis B virus","volume":"16","author":"Li","year":"2024","journal-title":"World J. Hepatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.3748\/wjg.v25.i27.3527","article-title":"Immune suppression in chronic hepatitis B infection associated liver disease: A review","volume":"25","author":"Li","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1136\/gutjnl-2017-314098","article-title":"Regulatory NK cells mediated between immunosuppressive monocytes and dysfunctional T cells in chronic HBV infection","volume":"67","author":"Li","year":"2018","journal-title":"Gut."},{"key":"B41","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12967-017-1318-1","article-title":"Veritable antiviral capacity of natural killer cells in chronic HBV infection: an argument for an earlier anti-virus treatment","volume":"15","author":"Li","year":"2017","journal-title":"J. Transl. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1002\/imt2.76","article-title":"Decoding the role of immune T cells: A new territory for improvement of metabolic-associated fatty liver disease","volume":"2","author":"Liu","year":"2023","journal-title":"Imeta."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065327","article-title":"Virus-specific immune response in HBeAg-negative chronic hepatitis B: relationship with clinical profile and HBsAg serum levels","volume":"8","author":"Loggi","year":"2013","journal-title":"PloS One"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.3969\/j.issn.1001-5256.2021.06.007","article-title":"Current status of the research on low \u2212 level viremia in chronic hepatitis B patients receiving nucleos( t) ide analogues","volume":"37","author":"Lu","year":"2021","journal-title":"J. Clin. Hepatalogy"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bsheal.2021.05.001","article-title":"Comprehensive investigation of HBV-related hepatocellular carcinoma and choice of anti-HBV therapy","author":"Lu","year":"2021","journal-title":"Biosafety Health"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00421","article-title":"Hepatitis B e Antigen Induces NKG2A+ Natural Killer Cell Dysfunction via Regulatory T Cell-Derived Interleukin 10 in Chronic Hepatitis B Virus Infection","volume":"8","author":"Ma","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1016\/j.cgh.2021.07.036","article-title":"Treatment algorithm for managing chronic hepatitis B virus infection in the United States: 2021 update","volume":"20","author":"Martin","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1053\/j.gastro.2012.08.046","article-title":"Altered functions of plasmacytoid dendritic cells and reduced cytolytic activity of natural killer cells in patients with chronic HBV infection","volume":"143","author":"Martinet","year":"2012","journal-title":"Gastroenterology."},{"key":"B49","doi-asserted-by":"publisher","first-page":"8308","DOI":"10.1128\/JVI.00833-10","article-title":"Clonal expansion of normal-appearing human hepatocytes during chronic hepatitis B virus infection","volume":"84","author":"Mason","year":"2010","journal-title":"J. Virol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1111\/liv.14482","article-title":"Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B","volume":"40","author":"Ogawa","year":"2020","journal-title":"Liver Int."},{"key":"B51","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/jvh.13979","article-title":"Assessment of HBV variants and novel viral and immune biomarkers in chronic hepatitis B patients with metabolic dysfunction associated steatotic liver disease","volume":"31","author":"Patel","year":"2024","journal-title":"J. Viral Hepat."},{"key":"B52","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41575-018-0089-3","article-title":"Metabolic aspects in NAFLD, NASH and hepatocellular carcinoma: the role of PGC1 coactivators","volume":"16","author":"Piccinin","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/jvh.13942","article-title":"Antiviral therapy response in patients with chronic hepatitis B and fatty liver: A systematic review and meta-analysis","volume":"31","author":"Rui","year":"2024","journal-title":"J. Viral Hepat."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024","article-title":"Peripheral NK cell phenotypic alteration and dysfunctional state post hepatitis B subviral particles stimulation in CHB patients: evading immune surveillance","volume":"15","author":"Selim","year":"2024","journal-title":"Front. Immunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"16003","DOI":"10.1073\/pnas.0607837103","article-title":"PGC-1alpha controls hepatitis B virus through nutritional signals","volume":"103","author":"Shlomai","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1611976","article-title":"Anti-HBV treatment partially restores the dysfunction of innate immune cells and unconventional T cells during chronic HBV infection","volume":"16","author":"Shu","year":"2025","journal-title":"Front. Immunol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1111\/jvh.13185","article-title":"The risk of hepatocellular carcinoma among chronic hepatitis B virus-infected patients outside current treatment criteria","volume":"26","author":"Sinn","year":"2019","journal-title":"J. Viral Hepat."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1016\/j.cgh.2020.03.001","article-title":"Persistent low level of hepatitis B virus promotes fibrosis progression during therapy","volume":"18","author":"Sun","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1002\/hep.1840210646","article-title":"Hepatic lidocaine metabolism in chronic hepatitis C virus hepatitis with or without steatosis","volume":"21","author":"Taliani","year":"1995","journal-title":"Hepatology."},{"key":"B60","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","article-title":"Hepatitis B virus infection","volume":"384","author":"Tr\u00e9po","year":"2014","journal-title":"Lancet."},{"key":"B61","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/978-981-13-9151-4_2","article-title":"HBV genome and life cycle","volume":"1179","author":"Wang","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.221","article-title":"Cell-type-specific expression analysis of liver transcriptomics with clinical parameters to decipher the cause of intrahepatic inflammation in chronic hepatitis B","volume":"3","author":"Wang","year":"2024","journal-title":"Imeta."},{"key":"B63","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.virs.2023.10.007","article-title":"Recent advances in understanding T cell activation and exhaustion during HBV infection","volume":"38","author":"Wang","year":"2023","journal-title":"Virol. Sin."},{"key":"B64","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.xphs.2016.12.003","article-title":"Development of a novel formulation that improves preclinical bioavailability of tenofovir disoproxil fumarate","volume":"106","author":"Watkins","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.immuni.2014.12.006","article-title":"Regulatory T cells control antigen-specific expansion of Tfh cell number and humoral immune responses via the coreceptor CTLA-4","volume":"41","author":"Wing","year":"2014","journal-title":"Immunity."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1111\/liv.13716","article-title":"ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B","volume":"38","author":"Wong","year":"2018","journal-title":"Liver Int."},{"key":"B67","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/ID9.0000000000000128","article-title":"Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection (Text extract): executive summary","volume":"4","year":"2024","journal-title":"Infect. Dis. Immun."},{"key":"B68","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.2147\/IDR.S463843","article-title":"Non-invasive monitoring of the impact of low-level viremia on liver fibrosis in treated chronic hepatitis B patients","volume":"17","author":"Xu","year":"2024","journal-title":"Infect. Drug Resist."},{"key":"B69","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1080\/22221751.2019.1625728","article-title":"Down-regulation of cell membrane localized NTCP expression in proliferating hepatocytes prevents hepatitis B virus infection","volume":"8","author":"Yan","year":"2019","journal-title":"Emerg. Microbes Infect."},{"key":"B70","doi-asserted-by":"publisher","first-page":"666\u2013676","DOI":"10.3748\/wjg.v27.i8.666","article-title":"New therapeutic options for persistent low-level viremia in patients with chronic hepatitis B virus infection: Increase of entecavir dosage","volume":"27","author":"Yin","year":"2021","journal-title":"World J. Gastroenterol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1097\/CM9.0000000000001793","article-title":"Low-level viremia in nucleoside analog-treated chronic hepatitis B patients","volume":"134","author":"Zhang","year":"2021","journal-title":"Chin. Med. J. (Engl)"},{"key":"B72","doi-asserted-by":"publisher","first-page":"10040","DOI":"10.1016\/j.dcit.2025.100040","article-title":"Genotype switching in hepatitis B virus as a potential risk for vertical transmission from mother-to-child was first reported","volume":"3","author":"Zhang","year":"2025","journal-title":"Decoding Infection Transm"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.15(5)2015.27909","article-title":"Saturated Fatty Acid inhibits viral replication in chronic hepatitis B virus infection with nonalcoholic Fatty liver disease by toll-like receptor 4-mediated innate immune response","volume":"15","author":"Zhang","year":"2015","journal-title":"Hepat Mon."},{"key":"B74","doi-asserted-by":"publisher","first-page":"850\u2013859","DOI":"10.14218\/JCTH.2021.00046","article-title":"Chronic hepatitis B infection with low level viremia correlates with the progression of the liver disease","volume":"9","author":"Zhang","year":"2021","journal-title":"J. Clin. Transl. Hepatol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"67","DOI":"10.14218\/JCTH.2022.00066","article-title":"Adverse effect of nonalcoholic fatty liver disease on the therapeutic response in patients with chronic hepatitis B","volume":"11","author":"Zhang","year":"2023","journal-title":"J. Clin. Transl. Hepatol."},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1075916","article-title":"Hepatitis B functional cure and immune response","volume":"13","author":"Zheng","year":"2022","journal-title":"Front. Immunol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1093\/infdis\/jiy097","article-title":"Increased NK cell function after cessation of long-term nucleos(t)ide analogue treatment in chronic hepatitis B is associated with liver damage and HBsAg loss","volume":"217","author":"Zimmer","year":"2018","journal-title":"J. Infect. Dis."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1663858\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:38:12Z","timestamp":1763534292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1663858\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":77,"alternative-id":["10.3389\/fcimb.2025.1663858"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2025.1663858","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"article-number":"1663858"}}